Arthneeti
WB

Windlas Biotech Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Windlas Biotech Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹993
Market cap₹2.0K Cr
P/E29.5
Updated25 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

1 of 3 strong

RevenueRank 3
MarginRank 3
CapexYes

Not discussed on this call: fundraise, order book.

The short version

Company maintains focus on long-term growth across all three verticals: CDMO, Trade Generics & Institutional, and Exports. Windlas Biotech has demonstrated 14 consecutive quarters of consistent revenue growth, reflecting strong execution.

From Windlas Biotech Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 3
  • Company maintains focus on long-term growth across all three verticals: CDMO, Trade Generics & Institutional, and Exports.
  • CDMO vertical showed strong 29% Y-o-Y growth; volume growth expected to be higher than price effects.
  • Exports vertical has high potential with ongoing geography and portfolio expansion, plant approvals, and increased business development efforts.
  • Trade Generics impacted by discontinuation of codeine products but expected to progressively bridge the gap via new product launches and geographic expansion.
  • Capacity utilization with Plant 6 commissioning aims at INR1,100 crore revenue, with potential for 10-15% further increase via operational efficiencies.
  • Incremental capacity expansions preferred over large facilities to maintain operational control and optimize margins.
  • Growth will be driven by increasing product offerings, deepening geographic presence, and strong execution.
  • No specific quarterly guidance provided, but management remains confident in sustainable, multi-year growth.

Profitability & Margins

See what Windlas Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes
  • Plant 6 expansion is targeted to be operational by end of H1 FY2026, with full depreciation impact starting Q2/Q3.
  • Plant 6 is an incremental capacity expansion expected to add INR100-150 crores in revenue.
  • No immediate new large-scale capex plans currently; focus remains on incremental capacity additions rather than big facility projects.
  • Debottlenecking and operational capex will continue to optimize existing plants and improve efficiencies.
  • Capacity enhancement projects typically take 6-8 months for machinery installation and qualification.
  • Future capacity additions will be aligned with demand; no large unutilized capacity will be created to avoid low-margin pressure.
  • Discussions underway on potential new variants and capacity expansions but no finalized plans shared yet.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Windlas Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly provide details on the current or expected order book or pending orders for Windlas Biotech Limited. However, some relevant insights can be summarized as: - The company continues to expand its customer base and product portfolio, especially in the CDMO and Export verticals, indicating a growing order pipeline. - Plant 6 is expected to be commissioned by the end of Q2 FY27, which will enhance capacity and support increased order fulfillment. - Management emphasizes close customer negotiations and responsiveness to volatile API prices, reflecting active order management. - Discussions on capacity expansion involve a lead time of about 6-8 months to add machinery and qualify it. - No specific quantitative order book or pending order figures were disclosed during the call. Thus, while clear orderbook numbers are not shared, the overall tone suggests ongoing capacity utilization improvements and customer engagement aimed at supporting growing demand.

Windlas Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Windlas Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Windlas Biotech Ltd Q1 FY27 results?

Company maintains focus on long-term growth across all three verticals: CDMO, Trade Generics & Institutional, and Exports. Windlas Biotech has demonstrated 14 consecutive quarters of consistent revenue growth, reflecting strong execution.

What is Windlas Biotech Ltd share price analysis?

Windlas Biotech Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.5 with a market cap of ₹1,959 Cr. Investors should review the full earnings analysis for detailed insights.

Is Windlas Biotech Ltd planning capital expenditure?

Plant 6 expansion is targeted to be operational by end of H1 FY2026, with full depreciation impact starting Q2/Q3.

Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.